PIPECURONIUM

Pipecuronium is a non‑depolarizing neuromuscular blocker that competitively inhibits acetylcholine at nicotinic receptors, producing skeletal muscle paralysis during surgery. Side effects include prolonged paralysis, hypotension, histamine release, and respiratory depression requiring mechanical ventilation.

SKU: 360bd0b54591 Category: Tag:

Product Description


Mechanism of Action

PIPECURONIUM (ID 27121) demonstrates a broad, multi‑layer biochemical activity profile affecting enzyme‑driven catalytic pathways, receptor‑regulated signalling systems, mitochondrial bioenergetics, redox‑state equilibrium, ion‑channel behaviour, cytoskeletal integrity and transcription‑factor regulatory networks. Its structural features indicate potential interactions with catalytic residues, allosteric protein domains, membrane‑bound receptors and intracellular signalling intermediates, enabling influence over phosphorylation kinetics, Ca²⁺/cAMP/IP₃/DAG‑mediated second‑messenger systems, ATP turnover, ROS buffering and mitochondrial respiratory‑chain performance.

Depending on concentration and biological conditions, PIPECURONIUM may modulate metabolic flux distribution, alter mitochondrial membrane potential, influence chromatin accessibility, impact vesicular trafficking dynamics and reshape gene‑expression patterns relevant to survival, inflammation, apoptosis, autophagy, metabolic adaptation and redox‑stress response.

Benefits and Advantages

This compound is widely used across advanced biochemical, pharmacological and mechanistic research domains, including:

  • Receptor–ligand interaction studies and affinity‑mapping
  • Enzyme‑kinetic pathway deconstruction and catalytic‑domain profiling
  • Mitochondrial‑function analysis and ATP‑flux/oxidative‑stress modelling
  • Multi‑omics integration (transcriptomics, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal‑structure and membrane‑dynamics research
  • Autophagy, apoptosis, necroptosis and ferroptosis signalling investigations
  • SAR (structure–activity relationship) profiling and compound‑optimisation workflows
  • Pharmacodynamic modelling, threshold‑activation mapping and dose–response scaling

Side Effects and Risks

Laboratory‑observed or predicted risks include:

  • Oxidative imbalance and excessive ROS accumulation
  • Mitochondrial overload or respiratory‑chain suppression
  • Dysregulation of Na⁺/K⁺/Ca²⁺ ion‑channel homeostasis
  • Unintended receptor cross‑talk or inhibitory interference
  • Cytoskeletal destabilisation and membrane‑integrity disruption
  • Dose‑dependent cytotoxicity with apoptosis/autophagy activation
  • Transcriptional instability or epigenetic disturbance
  • Inflammatory signalling activation via NF‑κB, MAPK or JNK pathways

Use strictly within controlled laboratory environments under appropriate biosafety protocols.

Datasheet


Molecular Formula

C35H60N2O4

Molecular Weight

602.9 g/mol

CAS Number

68399-58-6

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

9.50e-05 g/L

Purity

Purity information is available upon request (COA).

Synonym

PIPECURONIUM; Pipecurium; 68399-58-6; 1N3O74HM92; DTXSID20860643

IUPAC/Chemical Name

[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate

InChl Key

OWWLUIWOFHMHOQ-XGHATYIMSA-N

InChl Code

InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/50192;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download